Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8TC12
UPID:
RDH11_HUMAN
Alternative names:
Androgen-regulated short-chain dehydrogenase/reductase 1; HCV core-binding protein HCBP12; Prostate short-chain dehydrogenase/reductase 1; Retinal reductase 1; Short chain dehydrogenase/reductase family 7C member 1
Alternative UPACC:
Q8TC12; A6NDK3; A8K062; B2RB26; B4DDW0; Q0QD40; Q6IAH5; Q9NRW0; Q9Y391
Background:
Retinol dehydrogenase 11 (RDH11) plays a pivotal role in the metabolism of retinoids, crucial for vision and cellular differentiation. Known by several names, including Androgen-regulated short-chain dehydrogenase/reductase 1 and Retinal reductase 1, RDH11 exhibits specificity for NADP and processes various forms of retinol. Its activity is essential for the conversion of retinol into retinal, a key intermediate in the visual cycle and in the biosynthesis of retinoic acid.
Therapeutic significance:
RDH11's involvement in Retinal dystrophy, juvenile cataracts, and short stature syndrome highlights its clinical significance. The disease's association with RDH11 mutations underscores the enzyme's role in ocular health and development. Understanding RDH11's function could lead to novel therapeutic strategies for managing retinal dystrophies and related disorders, offering hope for patients suffering from these debilitating conditions.